Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
The emergence of immune checkpoint inhibitors (ICIs) has dramatically changed the treatment landscape for patients with metastatic non-small cell lung cancer (NSCLC). These achievements inspired investigators and pharmaceutical companies to conduct clinical trials in patients with early-stage NSCLC...
Main Authors: | Junichi Soh, Akira Hamada, Toshio Fujino, Tetsuya Mitsudomi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/16/4035 |
Similar Items
-
Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
by: Yurong Peng, et al.
Published: (2023-01-01) -
Corrigendum: Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
by: Yurong Peng, et al.
Published: (2023-03-01) -
Perioperative systemic therapies for non-small-cell lung cancer: Recent advances and future perspectives
by: Savvas Lampridis, et al.
Published: (2023-01-01) -
Increasing cure rates of solid tumors by immune checkpoint inhibitors
by: Weijie Ma, et al.
Published: (2023-01-01) -
Current status and prospect of perioperative treatment of stage Ⅲ melanoma
by: XU Yu, CHEN Yong, YANG Jilong, ZHU Guannan
Published: (2022-12-01)